<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9716531</journal-id>
<journal-id journal-id-type="pubmed-jr-id">4938</journal-id>
<journal-id journal-id-type="nlm-ta">J Med Chem</journal-id>
<journal-id journal-id-type="iso-abbrev">J. Med. Chem.</journal-id>
<journal-title-group>
<journal-title>Journal of medicinal chemistry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0022-2623</issn>
<issn pub-type="epub">1520-4804</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31033289</article-id>
<article-id pub-id-type="pmc">6679956</article-id>
<article-id pub-id-type="doi">10.1021/acs.jmedchem.9b00068</article-id>
<article-id pub-id-type="manuscript">NIHMS1040077</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Consideration of Binding Kinetics in the Design of Stapled Peptide Mimics of the Disordered Proteins Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 and Eukaryotic Translation Initiation Factor 4G</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Gallagher</surname>
<given-names>Erin E.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="author-notes" rid="FN1">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>James M.</given-names>
</name>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="author-notes" rid="FN1">§</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Menon</surname>
<given-names>Arya</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mishra</surname>
<given-names>Lauren D.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chmiel</surname>
<given-names>Alyah F.</given-names>
</name>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garner</surname>
<given-names>Amanda L.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0870-3347</contrib-id>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="aff" rid="A1">†</xref>
<xref ref-type="aff" rid="A2">‡</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>†</label>Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 1600 Huron Parkway, NCRC B520, Ann Arbor, Michigan 48109, United States</aff>
<aff id="A2"><label>‡</label>Program in Chemical Biology, University of Michigan, 210 Washtenaw Avenue, Ann Arbor, Michigan 48109, United States</aff>
<author-notes>
<fn fn-type="other" id="FN1">
<label>§</label>
<p id="P1">E.E.G. and J.M.S. contributed equally.</p>
</fn>
<corresp id="CR1"><label>*</label><bold>Corresponding Author</bold><email>algarner@umich.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>23</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>23</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>62</volume>
<issue>10</issue>
<fpage>4967</fpage>
<lpage>4978</lpage>
<!--elocation-id from pubmed: 10.1021/acs.jmedchem.9b00068-->
<abstract id="ABS1">
<p id="P2">Protein disorder plays a crucial role in signal transduction and is key for many cellular processes including transcription, translation, and cell cycle. Within the intrinsically disordered protein interactome, the <italic>α</italic>-helix is commonly used for binding, which is induced via a disorder-to-order transition. Because the targeting of protein—protein interactions (PPIs) remains an important challenge in medicinal chemistry, efforts have been made to mimic this secondary structure for rational inhibitor design through the use of stapled peptides. Cap-dependent mRNA translation is regulated by two disordered proteins, 4E-BP1 and eIF4G, that inhibit or stimulate the activity of the m<sup>7</sup>G cap-binding translation initiation factor, eIF4E, respectively. Both use an <italic>α</italic>-helical motif for eIF4E binding, warranting the investigation of stapled peptide mimics for manipulating eIF4E PPIs. Herein, we describe our efforts toward this goal, resulting in the synthesis of a cell-active stapled peptide for further development in manipulating aberrant cap-dependent translation in human diseases.</p>
</abstract>
<abstract abstract-type="graphical" id="ABS2">
<title>Graphcal Abstract</title>
<p id="P3">
<graphic orientation="portrait" position="float" xlink:href="nihms-1040077-f0009.jpg"></graphic>
</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>